Benchmark steps to sidelines on Haemonetics

• Benchmark cuts Haemonetics (NYSE:HAE) to Hold from Buy.
• Analyst John Wald is adopting a more cautious outlook "due to pressures from declines in the Whole Blood market and the impact of two tenders which have yielded lower pricing."
• Wald now sees negative growth in Whole Blood in 2015.
• Price target cut to $46 from $49.